🌐 ACHIEVE-1 Decoded: Efficacy & Safety of Orforglipron in Type 2 Diabetes

🚨 New Breakthrough in Type 2 Diabetes Care! 💊🧬 The ACHIEVE-1 trial shows that Orforglipron, a once-daily oral, nonpeptide GLP-1 receptor agonist, delivers significant reductions in HbA1c and body weight—without injections and with minimal restrictions! 🌍📉   👨‍⚕️ 559 patients across 5 countries ⏱️ 40 weeks, 3 dosing arms (3, 12, 36 mg) 📊 HbA1c ↓ by up to 1.48%, weight ↓ up to 7.6% ✅ No severe hypoglycemia 📌 Mild GI side effects during dose titration   This is a potential gamechanger for early T2DM care—simple, effective, and patient-friendly. 🚀 #Type2Diabetes #GLP1 #Orforglipron #Endocrinology #ClinicalTrials #PrecisionMedicine #Innovation #NEJM #ACHIEVE1 #OralTherapeutics 💥